Beryl Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Beryl Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-610,831	Closed	-$1.13M	–	30
2023 Q1	$1.13M	Buy	+610,831	New	+$757K	0.89%	14

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Beryl Capital Management's JNCE Position: Q2 2023 in Review

Beryl Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 610,831 shares — an estimated $1.13M sold.

Beryl Capital Management first reported a position in JNCE in Q1 2023 and held it in 1 quarter. The position peaked at $1.13M in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Beryl Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Beryl Capital Management sold 610,831 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.13M.
Beryl Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Beryl Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $1.13M in Q1 2023.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Beryl Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.